Amrit Ray, M.D., M.B.A. joined the Ultragenyx Board in April 2022. He currently serves as Chief Patient Officer for Biohaven Pharmaceuticals, a commercial-stage biopharmaceutical company focused on neurological and neuropsychiatric diseases. Prior to joining Biohaven, he was a Senior Advisor to Bain Capital Life Sciences, which invests in biopharmaceutical, medical device, diagnostics, and technology companies. Previously, Dr. Ray served as Global President, Head of R&D and Medical, and Executive Leadership Team member at Pfizer Upjohn where he oversaw all aspects of research, Phases I-IV development, regulatory, safety and medical affairs worldwide. Dr. Ray chaired the R&D Investment Committee and served as the company’s most senior decision-maker and spokesperson on patient matters. Before Pfizer, Dr. Ray was Chief Medical Officer and R&D Leadership Team Member for pharmaceuticals at Johnson & Johnson.
Dr. Ray earned degrees in Immunology and in Medicine at Edinburgh University, and an MBA at Dartmouth College’s Tuck School. He is a Visiting Professor of Practice at the Faculty of Medical Sciences, Newcastle University, UK, and a board member at the EveryLife Foundation for rare diseases.